Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 462.5 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2022 Q1 | 318.85 Million USD | 67.81% |
| 2022 FY | - USD | -100.0% |
| 2022 Q4 | -215.07 Million USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 Q2 | 215.07 Million USD | -32.55% |
| 2021 Q4 | 190.01 Million USD | 39.98% |
| 2021 Q1 | 43.82 Million USD | 0.0% |
| 2021 Q2 | 92.93 Million USD | 112.06% |
| 2021 Q3 | 135.74 Million USD | 46.06% |
| 2021 FY | 462.5 Million USD | 0.0% |
| 2020 Q2 | 9.69 Million USD | 742.57% |
| 2020 FY | - USD | 0.0% |
| 2020 Q3 | 17.66 Million USD | 82.14% |
| 2020 Q1 | 1.15 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ADC Therapeutics SA | 69.55 Million USD | 100.0% |
| Alto Neuroscience, Inc. | - USD | NaN% |
| Annovis Bio, Inc. | - USD | NaN% |
| Ginkgo Bioworks Holdings, Inc. | 251.45 Million USD | 100.0% |
| Nuvation Bio Inc. | - USD | NaN% |
| Nuvation Bio Inc. | - USD | NaN% |
| Arcus Biosciences, Inc. | 117 Million USD | 100.0% |
| Theriva Biologics, Inc. | - USD | NaN% |
| Zymeworks Inc. | 76.01 Million USD | 100.0% |